Skip to the main content.
Facebook Instagram Linkedin X YouTube Medium

megamenu-services

 

Turn Vision into Velocity with the Innovation CRO

Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.

All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.

Explore our Services

megamenu-solutions-expertise

 

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Solutions

Expertise

megamenu-company-2

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Explore our Company

Veranex Supports Philips Healthcare with Writing Manuscript of Medicare Claims Study of Mobile Cardiac Monitoring

admin.veranex : Mar 24, 2025 10:23:08 PM

Commercialization

By leading the manuscript development, Veranex supported Philips Healthcare in publishing real-world evidence data supporting the use of Mobile Cardiac Monitoring after a TAVR procedure.

Veranex Supports Retrospective Claims Analysis of Physical Therapy Utilization Among Women With Stress or Mixed Urinary Incontinence

admin.veranex : Mar 24, 2025 10:22:49 PM

Manasi Datar, Li-Chen Pan, and Thomas Goss, members of the Veranex Commercial Strategy and Market Access team, supported the retrospective...

Commercialization
Read More

Study by Veranex and Thermo Fisher Highlights Payer Budget Impact of Novel Test for Kidney Transplant Rejection

admin.veranex : Mar 24, 2025 10:23:06 PM

By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray...

Commercialization
Read More
Webinar – 2024 IVDR Sprint Series: Usability and Human Factors: Cornerstones of Near Patient Testing – Insights and Perspectives from a Notified Body

Webinar – 2024 IVDR Sprint Series: Usability and Human Factors: Cornerstones of Near Patient Testing – Insights and Perspectives from a Notified Body

Veranex : Mar 24, 2025 10:22:44 PM

Near-patient testing (NPT) devices face substantial challenges under the new IVDR, including: New Stringent Regulatory Constraints due to IVDR

IVD Human Factors
Read More